TIL · Instil Bio, Inc. · Financials
The latest filing states the doubt was alleviated.
“As discussed above and in Note 10 to the accompanying condensed consolidated financial statements, the 2024 Loan is due in January 2027, for total principal of $85.6 million, which is in excess of cash, cash equivalents, and marketable securities on hand as of June 30, 2026, which we concluded is an indicator of substantial doubt about our ability to continue as a going concern. We concluded that management's plans, including Complex Therapeutics LLC's contractual right to exercise the extension option to January 2028, which is within Complex Therapeutics LLC's control, alleviate the conditions that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|---|
| — | — | — | — | — | $0 | $138K | |
| $8.97M | $8.97M | $4.27M | $0 | — | — | — | |
| $13.56M | $24.74M | $11.84M | $39.6M | $141.06M | $107.25M | $19.4M | |
| $22.43M | $27.22M | $44.21M | $47.55M | $62.24M | $48.31M | $14.38M | |
| $284K | $534K | $3.61M | $4.76M | $5.99M | $2.75M | $256K | |
| $37.17M | $78.58M | $73.54M | $159.17M | $226.46M | $155.56M | $33.78M | |
| -$37.17M | -$78.58M | -$73.54M | -$159.17M | -$226.46M | -$155.56M | -$33.64M | |
| — | — | — | — | — | — | -24379.71% | |
| -$36.89M | -$78.05M | -$69.93M | -$154.41M | -$220.47M | -$152.81M | -$33.39M | |
| $6.28M | $5.83M | $8.99M | $5.21M | $1.88M | $0 | — | |
| -$365K | $212K | -$2.86M | -$575K | -$564K | -$1.28M | -$3.94M | |
| — | -$71.37M | -$74.14M | -$156.09M | -$225.25M | -$156.76M | -$37.59M | |
| — | $0 | — | $0 | -$2.07M | $39K | $151K | |
| -$30.28M | -$71.37M | -$74.14M | -$156.09M | -$223.18M | -$156.79M | -$37.74M | |
| — | — | — | — | — | — | -27346.38% | |
| -$30.06M | -$71.73M | -$74.02M | -$155.94M | -$223.58M | -$156.6M | -$38.02M | |
| USD/shares | -$4.39 | -$10.70 | -$11.39 | -$24.00 | -$34.46 | -$29.60 | -$47.20 |
| USD/shares | -$4.39 | -$10.70 | -$11.39 | -$24.00 | -$34.46 | -$29.60 | -$47.20 |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 799.89K |
| shares | — | 6.67M | 6.51M | 6.5M | 6.48M | 5.3M | 799.89K |
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Noncurrent loans payable | 2026-06-30 | USD 85,192,000 | 10-Q filed 2026-08-13 |
| Operating lease liabilities | 2026-06-30 | USD 2,228,000 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 296 similar-size Biotechnology companies (of 559 listed).